Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
Subscribe To Our Newsletter & Stay Updated
